Zach Bohannan

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Guillermo Garcia‐Manero, H. Jean Khoury, Elias Jabbour et al. · Clinical Cancer Research · 2014 · 54 citations · Full text

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Talha Badar, Keyur P. Patel, Philip A. Thompson et al. · Leukemia Research · 2015 · 52 citations · Full text

Mutation-based Testing, Engineering, Somatic Variant +9

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

Mónica Cabrero, Elias Jabbour, Farhad Ravandi et al. · Leukemia Research · 2015 · 51 citations · Full text

Hematological Malignancy, Agent Therapy, Medicine +9

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Guillermo Montalban‐Bravo, Xianbao Huang, Elias Jabbour et al. · Leukemia · 2016 · 40 citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +10

Assessing Side-Chain Perturbations of the Protein Backbone: A Knowledge-Based Classification of Residue Ramachandran Space

David B. Dahl, Zach Bohannan, Qianxing Mo et al. · Journal of Molecular Biology · 2008 · 36 citations · Full text

Biochemistry, Biomolecular Structure Prediction, Protein Folding +12